35 results
8-K
EX-2.2
ORTX
Orchard Therapeutics plc
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
and personnel with an appropriate level of education, experience and training for the relevant obligation, (ii) shall cause Apple to promptly assign
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
and describes all Training Data that is material to (i) the development of the AI Technology developed and/or used by Apple or its Subsidiaries; or (ii … Training Data disclosed or required to be disclosed in Section 4.20(g) of the Apple Disclosure Schedule, including the end user license agreement or other
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
Subsidiaries.
(g) Section 4.20(g) of the Apple Disclosure Schedule accurately identifies and describes all Training Data that is material to (i … . Apple and its Subsidiaries have complied with all contractual terms applicable to any Training Data disclosed or required to be disclosed in Section
DEFA14A
ORTX
Orchard Therapeutics plc
5 Oct 23
Additional proxy soliciting materials
9:07am
identifies and describes all Training Data that is material to (i) the development of the AI Technology developed and/or used by Apple or its … applicable to any Training Data disclosed or required to be disclosed in Section 4.20(g) of the Apple Disclosure Schedule, including the end user license
8-K
EX-2.1
sveesnj0hliseefr
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
heqxyl d94382d
14 Sep 21
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
7:00am